Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Institutional Review Board/ International Ethics Committee approved Informed Consent obtained~2. Ability to understand and comply with the study requirements and able to provide written informed consent~3. Age ≥18 and \<85 years~4. Estimated glomerular filtration rate (eGFR) is ≥30 mL/min/1.73 m2~5. Subject is scheduled for non-emergent coronary artery bypass grafting (CABG) surgery and/or valve surgery and/or ascending aorta aneurysm surgery with use of cardiopulmonary bypass (CPB), and AKI risk factors are present at screening~6. Female subject is not of child-bearing potential, or agreeing not to become pregnant~7. Female subject must not be breastfeeding~8. Female subject must not donate ova~9. Male subject and their female spouse/partner(s) who are of childbearing potential must be using a highly effective form of birth control~10. Male subjects must not donate sperm~11. Subject agrees not to participate in another interventional study~Exclusion Criteria:~1. Medical condition that makes the subject unsuitable for study participation~2. Scheduled for emergent surgeries (eg, aortic dissection)~3. Scheduled for CABG and/or valve surgery and/or ascending aorta aneurysm surgery combined with additional non-emergent cardiac surgeries (eg, congenital heart defects)~4. Scheduled to undergo transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR), or off-pump surgeries or left ventricular assist device (LVAD) implantation~5. Experiences a cardiogenic shock or hemodynamic instability which require inotropes or vasopressors or other mechanical devices within 24 hours prior to surgery~6. Requirement for defibrillator or permanent pacemaker, mechanical ventilation, intraaortic balloon pumping (IABP), LVAD, or other forms of mechanical circulatory support (MCS)~7. Diagnosed with AKI (as defined by KDIGO criteria) within 3 months prior to surgery~8. Required cardiopulmonary resuscitation within 14 days prior to cardiac surgery~9. Ongoing sepsis or an untreated diagnosed clinically significant infection (viral or bacterial)~10. Total bilirubin or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2 times the upper limit of normal (ULN)~11. History of solid organ transplantation~12. History of renal replacement therapy (RRT)~13. Medical condition which requires active immunosuppressive treatment~14. Severe allergic asthma~15. Ongoing chemotherapy or radiation therapy for malignancy that may have an impact on kidney function~16. Received an investigational medicinal product within the last 90 days (or within 5 half-lives of the investigational drug, whichever is longer)~17. Subject has a known allergy to RMC-035 or one of its constituents, or has previously received RMC-035

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- RMC-035 (Type: EXPERIMENTAL): RMC-035 is a concentrate (6.0 mg/mL) for solution for infusion for IV administration.~Dosing will be based on renal function at Day -1: Subjects with eGFR ≥60 mL/min/1.73m2 will receive 1.3 mg/kg (per dose) for the first and second dose, followed by 0.65 mg/kg (per dose) for the third, fourth and fifth dose, while subjects with eGFR \>30 and \<60 mL/min/1.73m2 will receive 0.65 mg/kg (per dose) for all five doses Dosing occurs at time 0 and then after 6, 12, 24 and 48 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Identical to RMC-035 arm except that the placebo contains no active ingredient.

Based on this trial design, predict the completion outcome and termination type (if applicable).